SCHEMBL6882571

SCHEMBL6882571

COc1ccc(CCC(=O)O)c(C(=O)O)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.69
SMN1; SMN2 Q16637 1/20 0.51
HTT P42858 1/20 0.51
HSD17B10 Q99714 3/20 0.50
KDM4E B2RXH2 3/20 0.50
ALDH1A1 P00352 2/20 0.50
HPGD P15428 2/20 0.50
GPR17 Q13304 1/20 0.50
FFAR1 O14842 3/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2C19 P33261 1/20 0.48
PPARG P37231 1/20 0.47
PPARD Q03181 1/20 0.47
PPARA Q07869 1/20 0.47
CYP3A4 P08684 1/20 0.45
GAA P10253 1/20 0.45
NPC1 O15118 1/20 0.45
PKM P14618 1/20 0.45
RAB9A P51151 1/20 0.45
LMNA P02545 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26679226 0.92 POLB (0.59) POLBSMN1; SMN2HTTHSD17B10KDM4E
SCHEMBL13387961 0.84 POLB (0.50) POLBSMN1; SMN2HTTHSD17B10KDM4E
SCHEMBL1399960 0.83 HSD17B10 (0.63) POLBSMN1; SMN2HTTHSD17B10KDM4E
SCHEMBL13469239 0.83 SMN1; SMN2 (0.57) POLBSMN1; SMN2HSD17B10KDM4EALDH1A1
SCHEMBL25648716 0.82 POLB (0.71) POLBHTTHSD17B10KDM4EALDH1A1
SCHEMBL21317665 0.82 POLB (1.00) POLBHSD17B10ALDH1A1HPGDFFAR1
SCHEMBL2723938 0.82 POLB (0.77) POLBFFAR1
SCHEMBL20232560 0.82 POLB (0.71) POLBHTTHSD17B10KDM4EALDH1A1
SCHEMBL490637 0.82 POLB (0.71) POLBHTTHSD17B10ALDH1A1HPGD
SCHEMBL8482547 0.81 SMN1; SMN2 (0.56) POLBSMN1; SMN2HSD17B10KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040087655-A1 6-Substituted indanoyl amino acid conjugates as mimics to the biological activity of coronatine MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV (DE) 2004-05-06 US disclosed
EP-1351922-A2 6-SUBSTITUTED INDANOYL AMINO ACID CONJUGATES AS MIMICS TO THE BIOLOGICAL ACTIVITY OF CORONATINE Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2003-10-15 EP disclosed
WO-2002055480-A2 6-SUBSTITUTED INDANOYL AMINO ACID CONJUGATES AS MIMICS TO THE BIOLOGICAL ACTIVITY OF CORONATINE MAX PLANCK GESELLSCHAFT (DE) 2002-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087655-A1 6-Substituted indanoyl amino acid conjugates as mimics to the biological activity of coronatine CORO1C, CORO1A, AGER POLB 4155/4885SMN1; SMN2 4790/4885HTT 1965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.